[vc_row row_padding=”xt-padding-initial” el_class=”xt-banner-inner” css=”.vc_custom_1583267878093{background-image: url(/wp-content/uploads/2020/03/header-images_about-us.jpg?id=1765) !important;}”][vc_column][vc_column_text el_class=”xt-white”]
Humanitarian Story
[/vc_column_text][/vc_column][/vc_row][vc_row row_padding=”xt-padding-initial” css=”.vc_custom_1572531687039{padding-top: 60px !important;padding-bottom: 60px !important;}”][vc_column width=”2/3″][vc_column_text]Global Institute of Stem Cell Therapy and Research (GIOSTAR) was founded with a mission to serve mankind in the most profound way possible. Our goal was to deliver the most advanced, elite, and expensive science to the masses. GIOSTAR’s co-founder, Dr. Anand Srivastava, has devoted more than 20 years of his career to the advancement of stem cell biology, cancer, gene therapy, and other scientific disciplines.
In collaboration with GIOSTAR’s co-founder and CEO, Mr. Deven Patel, Dr. Srivastava succeeded in bringing this vision to fruition, to change the face of medicine.
Dr. Srivastava and Mr. Patel are poised to deliver great advancements to the impoverished masses of India. After several encounters with honorable Prime Minister of India, Shri Narendra Modi, a blessing for the less fortunate tribal population of India was born. In partnership with Mr. Modi and the Government of Gujarat, India, the team announced the development of the world’s largest stem cell treatment hospital in 2009. This partnership has given rise to numerous impressive achievements, including the 2011 inauguration of the world’s first dedicated stem cell treatment hospital in Ahmedabad, Gujarat State, India.
Among its many noble ambitions is the treatment of Sickle Cell Disease (SCD), which is a debilitating affliction that has ravaged the tribal populations of India, most notably the state of Gujarat. Predominantly seen in the central and western regions of the country, the incidence rate of the sickle cell gene has been estimated to be greater than 30% in various Scheduled Tribes. It is expected that there will be approximately 1.4 million SCD patients among the entire tribal population. In the state of Gujarat alone, researchers suspect approximately 70,000 Sickle Cell Disease patients. GIOSTAR aims to build upon this success, with the launch of a stem cell transplant program for four state governments in India, encompassing a total population of roughly 155 million. GIOSTAR was founded on a strong mission: leveraging the work of the most highly skilled research and clinical teams to offer less fortunate populations a chance to truly “live” beyond the simple motive of treating patients for profit, the organization is driven by the beautiful, inspiring ambition to give back to society in the most profound way possible.
I Admire People Who Dare to Dream. Power Belongs to Those Who Dare to Follow Their Dream.
So…. “Be the change that you wish to see in the world.” – Mahatma Gandhi.
[/vc_column_text][vc_row_inner][vc_column_inner][vc_video link=”https://youtu.be/zTkpPseIgWk”][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text]
REFERENCES:
Rao, V R. “Genetics and Epidemiology of Sickle Cell Anemia in India.” Advances in Pediatrics., U.S. National Library of Medicine, Sept. 1988, www.ncbi.nlm.nih.gov/pubmed/2907511.
LEHMANN, H, and M CUTBUSH. “Sickle-Cell Trait in Southern India.” Advances in Pediatrics., U.S. National Library of Medicine, 23 Feb. 1952, www.ncbi.nlm.nih.gov/pubmed/14896162.
Jain, D L, et al. “Newborn Screening Shows a High Incidence of Sickle Cell Anemia in Central India.” Advances in Pediatrics., U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/22712682.[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″][vc_widget_sidebar sidebar_id=”sidebar-1″][/vc_column][/vc_row]
